Alzheimer’s disease treatments that slow progression of the disease could significantly reduce the financial burden to U.S. state budgets, according to a new USC study.
The study outlines how states—which have been hit particularly hard by the COVID-19 pandemic—would see relief: Medicare would cover the costs of treating the disease, while Medicaid expenditures would be reduced due to fewer patients entering nursing homes.
Assuming a 40% relative reduction of Alzheimer’s disease progression rates with treatment, researchers projected two decades of savings beginning in 2021, using a simulation model of state Medicaid…
